Recognition and management of extended spectrum beta lactamase producing organisms (ESBL).
ESBL organisms provide a continuing challenge in the geriatric community. They are increasingly prevalent, and pose unique challenges in treatment. Carbapenems are the mainstay of therapy; however they are expensive medications that require prolonged intravenous administration. Carbapenem resistance is a growing concern among frequently hospitalized patients and nursing home residents, and options for treatment of MDROs are limited. Attempts at minimizing the spread of beta-lactamase producers through hygiene and contact precautions are imperative, as is ongoing research into more effective antimicrobial agents.
Rhode Island Hospital/The Warren Alpert Medical School of Brown University, USA.
Sophia
S
Fircanis
Maria
M
McKay
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001431:Bacteriological Techniques; D004351:Drug Resistance; D004755:Enterobacteriaceae / Q000201:enzymology; D004756:Enterobacteriaceae Infections / Q000382:microbiology* / Q000517:prevention & control; D006801:Humans; D017053:Infection Control; D008826:Microbial Sensitivity Tests; D012307:Risk Factors; D016482:Urinalysis / Q000379:methods; D014552:Urinary Tract Infections / Q000382:microbiology* / Q000517:prevention & control; D001618:beta-Lactamases / Q000096:biosynthesis*
D000900:Anti-Bacterial Agents; D001618:beta-Lactamases